

Table S27: Percent of IgG+ B cells or plasmablasts that are epitope-specific (KO-GT8++) testing between vaccine dose among detectable response participants. Testing was done using the Wilcoxon rank-sum test (two-sided, $\alpha = 0.05$) and p values less than 0.05 are highlighted. Median, minimum, and maximum values are presented by treatment group and time point.

	Sample Type	Sample Sizes	Median (Range)	P Value
20µg vs. 100µg				
Wk3 (V05)	FNA/IgG GC B cells	12 vs. 13	17.7883 [0.4208, 50.8186] vs. 4.1046 [0.3949, 22.0344]	0.0114
Wk4 (V06)	PBMCs/IgG memory B cells	18 vs. 18	0.0528 [0.0149, 0.2292] vs. 0.0724 [0.0241, 0.4719]	0.1516
Wk8 (V07)	PBMCs/IgG memory B cells	18 vs. 17	0.0235 [0.0056, 0.1231] vs. 0.0385 [0.0116, 0.1537]	0.1949
Wk9 (V07A)	Fresh PBMCs/IgD- PBs	18 vs. 17	5.3287 [0.1217, 26.1824] vs. 1.3195 [0.2156, 5.3007]	0.0043
Wk10 (V08)	PBMCs/IgG memory B cells	17 vs. 17	0.3370 [0.0889, 0.8924] vs. 0.5124 [0.1403, 2.5581]	0.3223
Wk11 (V09)	FNA/IgG GC B cells	12 vs. 10	14.3631 [0.1418, 67.2531] vs. 1.2268 [0.1227, 4.0690]	0.1402
Wk16 (V10)	PBMCs/IgG memory B cells	18 vs. 16	0.1499 [0.0341, 0.3737] vs. 0.2482 [0.0305, 0.8489]	0.0946